Facts and figures

in page functions
[French]

The evidence is clear: vaccines are one of the most cost-effective investments in health and development in history. Gavi helps save children’s lives and protect people’s health by increasing equitable use of vaccines in lower-income countries.

More than 8 million deaths averted

Since its inception in 2000, Gavi has helped developing countries to prevent more than 8 million future deaths through its support to 10 vaccines: pentavalent, pneumococcal, rotavirus, yellow fever, meningitis A, Japanese encephalitis, human papillomavirus, measles second dose, measles-rubella and rubella.

Source: Gavi, the Vaccine Alliance/Bill & Melinda Gates Foundation 2016

Close to 580 million children immunised

Since 2000, Gavi support has contributed to the immunisation of close to 580 million children.

Source: WHO/UNICEF 2016

Reaching 81% coverage with DTP3

In 2015, coverage with three doses of diphtheria-tetanus-pertussis vaccine-containing vaccine (DTP3), including pentavalent vaccine, in Gavi-supported countries reached 81% – just 5 percentage points below the global average. This represents an increase of 21 percentage points since our foundation in 2000.

Source: WHO/UNICEF 2016

More than 65 million children immunised in 2015

In 2015 alone, more than 65 million children were immunised with Gavi-supported vaccines. This equates to over 195 million points of contact between these children and the primary health system and can provide a robust platform for other health interventions.

Source: WHO/UNICEF 2016

Health systems and immunisation services strengthened in more than 60 countries

The Vaccine Alliance has helped to strengthen health systems and immunisation services and increase injection safety in more than 60 countries.

Source: Gavi

More than 4 million deaths averted between 2011 and 2015

The Vaccine Alliance’s support for vaccines contributed to averting more than 4 million future deaths between 2011 and 2015.

Source: Gavi, the Vaccine Alliance/Bill & Melinda Gates Foundation 2016

277 million children immunised 2011–2015

Gavi support helped countries to immunise 277 million children between 2011 and 2015.

Source: WHO/UNICEF 2016

Over 200 vaccine introductions between 2011 and 2015

Gavi supported more than 200 vaccine introductions and campaigns in the 2011–2015 period – four times as many as in the previous five years.

Source: Gavi

Return on investment of immunisation: US$ 18 for every US$ 1 spent

A study in Health Affairs covering 73 Gavi-supported countries over the 2011–2020 period shows that, for every US$ 1 spent on immunisation, US$ 18 are saved in healthcare costs, lost wages and lost productivity due to illness. If we take into account the broader benefits of people living longer, healthier lives, the return on investment rises to US$ 48 per US$ 1 spent.

Source: Ozawa S, Clark S, Portnoy A et al. Return on investment from childhood immunizations in low- and middle-income countries, 2011-20, Health Affairs 2016

Gavi supports 12 new and underused vaccines

Pentavalent vaccine: 73 countries, 296 million children, 5 antigens

In July 2014, South Sudan became the final Gavi-supported country to introduce the five-in-one pentavalent vaccine. By the end of 2015, 296 million children had been immunised with pentavalent vaccine with Gavi support.

Source: WHO/UNICEF 2016

76 million children vaccinated against pneumococcal disease

By the end of 2015, Gavi had contributed to immunising 76 million children against pneumococcal disease. Gavi surpassed its 2015 target of 45 introductions already in 2014 – more than one year ahead of schedule. By the end of 2015, three-quarters of all Gavi-supported countries had introduced the vaccine.

Source: WHO/UNICEF 2016

More than 36 million children vaccinated against rotavirus

Vaccine Alliance support has contributed to immunising more than 36 million children against rotavirus diarrhoea. By the end of 2015, more than half of all Gavi-supported countries had introduced the vaccine.

Source: WHO/UNICEF 2016

235 million people immunised against meningitis A

By the end of 2015, 16 countries in the African meningitis belt had collectively immunised 235 million people against meningitis A with support from Gavi.

Source: WHO/UNICEF 2016

Meningitis A, C, Y, W combination vaccine stockpile prevents outbreaks

Gavi funds a stockpile of multivalent vaccine to prevent outbreaks of meningitis A, C, W and Y. Doses from the stockpile played a critical role in controlling the 2015 meningitis C outbreak in Niger.

Source: Gavi 2016

Human papillomavirus vaccine demonstration programmes: 1 million girls reached

Since the first human papillomavirus (HPV) vaccine demonstration programme in Kenya in 2013, 1 million girls have been immunised with Gavi support. Gavi is already funding national HPV vaccine programmes in Rwanda and Uganda.

Source: Gavi 2016

10 million children immunised against polio

In September 2014, Nepal became the first country to introduce inactivated polio vaccine (IPV) with Gavi support. By the end of 2015, 38 countries had introduced the vaccine with our support, collectively immunising 10 million children.

Source: Gavi 2016

32 million reached with measles second dose vaccine

Since 2007, countries have immunised 32 million children with a second dose of measles vaccine with Gavi support. Gavi- funded measles campaigns have helped vaccinate another 118 million children in countries at high risk of outbreaks.

Source: WHO/UNICEF 2016

Measles-rubella vaccine reaches 164 million people

By the end of 2015, Gavi-funded measles-rubella catch-up campaigns, targeting the next generation of mothers and children aged 9 months to 14 years, had reached 164 million people.

Source: WHO/UNICEF 2016

Yellow fever vaccine: mass prevention campaigns and routine immunisation

Since 2011, Gavi-supported campaigns have protected over 98 million people in 14 countries. We have also helped 17 countries introduce yellow fever vaccine through routine immunisation, immunising more than 90 million children.

Source: Gavi 2016

Oral cholera vaccine stockpile helps vaccinate more than 1 million people

Since its creation in 2013, the global oral cholera vaccine stockpile has been used to vaccinate more than 1 million people; in 2015, campaigns took place in Bangladesh, Cameroon, Haiti, Malawi, Tanzania and South Sudan.

Source: Gavi 2016

Japanese encephalitis: Lao first to introduce vaccine with Gavi support

In April 2015, Lao PDR became the first country to introduce Japanese encephalitis (JE) vaccine with Gavi support. By the end of the year, 1.6 million children aged between 9 months and 14 years had been immunised against JE.

Source: Gavi 2016

Coverage and equity are at the core of our 2016–2020 strategy. While we continue to help countries introduce new vaccines, our focus is expanding to reach every child with these vaccines.

1.5 million children under five lose their lives to vaccine-preventable diseases every year

In 2012, approximately 6.6 million children died before the age of five. WHO estimates that 1.5 million of these deaths were due to vaccine-preventable diseases.

Source: WHO

19 million under-immunised

19 million infants remain under-immunised with three doses of DTP in the world each year. Almost one in five of all children in Gavi-supported countries miss out on a full course of this basic package of vaccines.

Source: WHO/UNICEF 2016

95% of children miss out on recommended vaccines

Over 95% of children in Gavi-supported countries do not yet have access to all 11 vaccines recommended by WHO for infants in all countries.

Source: WHO/UNICEF 2015

80% of under-immunised children are in 20 countries

Approximately 80% of the under-immunised children in Gavi-supported countries live in just 20 countries, many of which are also fragile or conflict-afflicted. We are intensifying our efforts to improve coverage and equity in these priority countries.

Source: WHO/UNICEF 2016

Over a quarter of child deaths are due to pneumonia and diarrhoea

Pneumonia and diarrhoea account for 26% of deaths in under-fives in Gavi-supported countries.

Source: CHERG-WHO 2014

One woman dies every 2 minutes from cervical cancer

One woman dies from cervical cancer every two minutes – or 266,000 a year – over 85% in the developing world. Two-thirds of all cervical cancer deaths can be prevented with HPV vaccines.

Source: WHO

90,000 born with birth defects due to rubella

Every year, 90,000 babies in Gavi countries are born with severe birth defects known as congenital rubella syndrome because their mothers were infected with rubella during pregnancy. The combined measles-rubella vaccine, which Gavi supports, can help prevent this devastating disease.

Source: WHO

Pentavalent, pneumococcal and rotavirus vaccines: 43% reduction since 2010

The total cost of fully immunising a child with pentavalent, pneumococcal and rotavirus vaccines fell by 43% from US$ 35 in 2010 to US$ 20 in 2015.

Pentavalent (DTP-hep B-Hib) vaccine: a reduction of 44% to US$ 1.68 per dose

The weighted average price of pentavalent vaccine per dose dropped from US$ 2.98 in 2010 to US$ 1.68 in 2015, and is expected to decrease further to US$ 0.79 by 2019.

Pneumococcal vaccine: more than 90% price reduction through the AMC

Through the Advance Market Commitment (AMC), pneumococcal vaccines are available to Gavi-supported countries at no more than US$ 3.50 per dose, a more than 90% reduction compared with the public price in the USA. In 2016, Gavi secured a lowest price offer for one type of pneumococcal vaccine of US$ 3.05 per dose.

Rotavirus vaccine: 67% reduction to US$ 2.50

As a result of long-term supply agreements with manufacturers signed in 2012, Gavi buys the bulk of its rotavirus vaccine doses at €1.88 per dose (approximately US$ 2.50 per dose and US$ 5 per course), a two-thirds reduction compared to the previous lowest price offered to Gavi of US$ 7.50 a dose (US$ 15 a course). This will have an expected market impact valued at US$ 650 million.

Inactivated polio vaccine: available to Gavi countries from €0.75

The inactivated polio vaccine is available to Gavi-supported countries from as little as €0.75 (approximately US$ 1) per dose. Middle-income countries are able to buy the vaccine through UNICEF for between €1.49 and €2.40 (approximately US$ 2.04–3.28) per dose.

Human papillomavirus (HPV) vaccine: two-thirds reduction to US$ 4.50

Gavi, the Vaccine Alliance works with manufacturers to bring down HPV vaccine prices. In 2013, a price of US$ 4.50 per dose for one of the vaccines was agreed, a two-thirds reduction on the previous lowest public price.

Manufacturing base grown from 5 to 16 manufacturers – over half in emerging markets

2001: 5 vaccine manufacturers producing prequalified, appropriate Gavi vaccines – 1 based in an emerging market*

2015: 16 vaccine manufacturers producing prequalified, appropriate Gavi vaccines – 9 based in emerging markets


Sources: Gavi, the Vaccine Alliance, UNICEF Supply Division and CDC vaccine price list, 2016.
* Emerging markets are low- and middle-income countries as defined by the World Bank country classification, 2016.

Accelerating impact

Between 2016 and 2020, Gavi will help countries to immunise another 300 million children against potentially fatal diseases, saving between 5 and 6 million lives in the long term.

Reaching more children

We will also help increase the percentage of children in Gavi-supported countries who are immunised with the 11 vaccines recommended by WHO for infants everywhere, from 5% to 50% by 2020.

Country co-financing to reach US$ 1 billion in 2016–2020

Co-financing is key to the long-term sustainability of immunisation programmes. Countries’ co-financing payments are expected to amount to approximately US$ 1 billion in the 2016–2020 period.

Four countries transition out of Gavi support in January 2016

Gavi continues to help countries to build sustainable immunisation programmes. Four countries started to fully self- finance their vaccines in early 2016; close to 20 others are preparing to transition out of Gavi support by 2020.

100 million illness cases averted

Vaccines have a long-term positive impact beyond health outcomes. Expanded immunisation in Gavi-supported countries from 2016 to 2020 could deliver more than 100 million illness cases averted. This will reduce the burden of care on parents, improving their productivity and freeing them from crippling medical costs. And by protecting children from infectious diseases, vaccines will also help raise IQ levels.

Source: Lee LA et al. The estimated mortality impact of vaccinations forecast to be administered during 2011–2020 in 73 countries supported by the Gavi, the Vaccine Alliance. Vaccine 2013

US$ 80-100 billion in economic benefits

Investing in Gavi’s 2016-2020 strategy has the potential to deliver US$ 80-100 billion in costs averted related to illness, such as productivity loss due to death/disability, treatment costs, caretaker productivity loss and transport costs.

Source: Stack M et al. Estimated economic benefits during Decade of Vaccines, Health Affairs 2011

close icon

modal window here